Everolimus (Afinitor®)

Assessment Status Rapid review complete
Drug Everolimus
Brand Afinitor®
Indication Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor
Assessment Process
Rapid review commissioned 21/06/2012
Rapid review completed 12/10/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.